IGC Pharma, Inc.
IGC · AMEX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.00 | 0.06 | -0.07 |
| FCF Yield | -24.20% | -20.40% | -42.95% | -17.29% |
| EV / EBITDA | -3.17 | -2.96 | -1.39 | -2.61 |
| Quality | ||||
| ROIC | -113.09% | -127.48% | -75.07% | -62.92% |
| Gross Margin | 48.70% | 54.50% | 48.52% | 48.87% |
| Cash Conversion Ratio | 0.67 | 0.40 | 0.61 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.74% | 50.19% | 0.48% | -53.97% |
| Free Cash Flow Growth | 7.65% | 25.46% | 6.56% | 33.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | 0.09 | 0.25 | 0.69 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.40 | 0.18 | 0.06 |
| Cash Conversion Cycle | 289.14 | 468.03 | 1,703.16 | 5,164.42 |